Meqsel 0.5 Tablet

• Melanoma (a type of skin cancer)

Meqsel 0.5 Tablet can cause multiple side effects, most of which are mild to moderate and often temporary. Patients are advised to inform their healthcare provider immediately if symptoms stays for prolonged period of time.      

Common side effects include:

• Rash
• Diarrhea
• Lymphedema
• Fever
• Chills
• Nausea
• Vomiting
• Abdominal pain
• Peripheral edema
• Cough
• Headache
• Joint pain
• Night sweats
• Decreased appetite
• Constipation
• Muscle pain

• The dosage and duration of the Meqsel 0.5 Tablet are decided by the doctor based on the severity of the disease and other health factors. Take this tablet on an empty stomach for better results. Before starting this medicine, please inform your doctor about your medical history.
• If you experience any signs and symptoms while eating this medication that are not manageable, do not ignore those symptoms because they may lead to a higher risk.
  

• Meqsel 0.5 Tablet is a prescription based targeted anticancer medicine. It contains trametinib as an active ingredient which is a MEK inhibitor. It works by inhibiting the action of specific proteins known as MEK1 and MEK2 to slow or stop the growth of cancer cells.
• As an specific genetic mutation such as BRAF mutation causes an abnormal protein that sends continuous signals to MEK proteins which promote cancer cells to multiply uncontrollably. By interfering with the action of abnormal protein it effectively controls the progression of cancer.
  
  

• Khan, Z. M., Real, A. M., Marsiglia, W. M., Chow, A., Duffy, M. E., Yerabolu, J. R., ... & Dar, A. C. (2020). Structural basis for the action of the drug trametinib at KSR-bound MEK. Nature, 588(7838), 509-514. https://pubmed.ncbi.nlm.nih.gov/32927473/
• Ascierto, P. A., Ferrucci, P. F., Fisher, R., Del Vecchio, M., Atkinson, V., Schmidt, H., ... & Ribas, A. (2019). Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma. Nature medicine, 25(6), 941-946. https://pubmed.ncbi.nlm.nih.gov/31171878/
• Banks, M., Crowell, K., Proctor, A., & Jensen, B. C. (2017). Cardiovascular effects of the MEK inhibitor, trametinib: a case report, literature review, and consideration of mechanism. Cardiovascular toxicology, 17(4), 487-493. https://pubmed.ncbi.nlm.nih.gov/28861837/
• Infante, J. R., Fecher, L. A., Falchook, G. S., Nallapareddy, S., Gordon, M. S., Becerra, C., ... & Messersmith, W. A. (2012). Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. The lancet oncology, 13(8), 773-781. https://pubmed.ncbi.nlm.nih.gov/22805291/
• Wright, C. J., & McCormack, P. L. (2013). Trametinib: first global approval. Drugs, 73(11), 1245-1254. https://pubmed.ncbi.nlm.nih.gov/23846731/
• Lugowska, I., Koseła-Paterczyk, H., Kozak, K., & Rutkowski, P. (2015). Trametinib: a MEK inhibitor for management of metastatic melanoma. OncoTargets and therapy, 2251-2259.  https://pubmed.ncbi.nlm.nih.gov/26347206/